Home > Healthcare > Pharmaceuticals > Finished Drug Form > Liver Cancer Drugs Market

Liver Cancer Drugs Market Share

Report ID: GMI9707
Published Date: May 2024
Report Format: PDF

Download Free Sample

Liver Cancer Drugs Market Share

The liver cancer drugs industry is highly competitive, with prominent players are driving market growth through strong sales of oncology drugs for liver cancer. The growing strategic initiatives, collaborations, advanced treatments, and a focus on R&D underscored the competitive dynamics in the market, thereby driving advancements and market growth.

Liver Cancer Drugs Market Companies

Some of the prominent players operating in the liver cancer drugs industry include:

AbbVie Inc.
Amgen Inc.
AstraZeneca Plc
Bayer AG
Bristol-Myers Squibb Company
Eisai Co., Ltd.
Exelixis, Inc.
F. Hoffmann-La Roche Ltd.
Johnson & Johnson
Merck & Co., Inc
Novartis AG
Sanofi SA
Thermo Fisher Scientific Inc.

Authors: Mariam Faizullabhoy, Gauri Wani

Frequently Asked Questions (FAQ) :

The market size of liver cancer drugs was reached USD 2.9 billion in 2023 and is estimated to grow at 11.8% CAGR from 2024 to 2032, owing to the rising incidence of liver cancer.

The hepatocellular carcinoma segment in the liver cancer drugs market generated USD 1.9 billion in 2023 and is predicted to reach USD 5 billion by 2032, due to its prevalence among individuals with chronic liver diseases such as cirrhosis.

North America liver cancer drugs market size exceeded USD 1.1 billion in 2023, attributed to the early adoption of advanced diagnostic tests and therapies for liver cancer.

AbbVie Inc., Amgen Inc., AstraZeneca Plc, Bayer AG, Bristol-Myers Squibb Company, Eisai Co., Ltd., Exelixis, Inc., F. Hoffmann-La Roche Ltd., Johnson & Johnson, Merck & Co., Inc, Novartis AG, Sanofi SA, and Thermo Fisher Scientific Inc.